Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin
Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin Herantis Pharma Plc.Company release 13 November 2015, 9:00 am Finnish Medicines Agency Fimea has authorized Herantis Pharma Plc's ("Herantis") first-in-man clinical study of Lymfactin® for the treatment of breast-cancer associated lymphedema. Patient recruitment in the clinical study is planned to begin in Finland in the first half of 2016. "There are no approved medicines for breast-cancer associated lymphedema", says Burkhard Blank, MD, Chief Medical Officer of Herantis. "The symptoms are